Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

The pharmaceutical company Novo Nordisk has products sold under the Novolin brand name, and Eli Lilly ... (short-acting), NPH (intermediate-acting), or premixed NPH/regular insulin without a ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Two years ago, Eli ... insulin market. Lilly has been under pressure in the US over its pricing for insulin products, and earlier this year launched a generic of its own Humalog brand of fast ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...